-
1 week ago | 
onlinelibrary.wiley.com | Fang-Yuan Chen |Rong Fu |Zhihao Gong |Chunju Li
Aqueous-phase molecular recognition pairs with ultrahigh binding affinity hold immense value in biotechnology and chemical applications. However, the rational design of synthetic pairs with such exceptional binding strength has long remained a significant challenge, with notable progress achieved only in recent years.
-
1 week ago | 
pericles.pericles-prod.literatumonline.com | Fang-Yuan Chen |Rong Fu |Zhihao Gong |Chunju Li
Aqueous-phase molecular recognition pairs with ultrahigh binding affinity hold immense value in biotechnology and chemical applications. However, the rational design of synthetic pairs with such exceptional binding strength has long remained a significant challenge, with notable progress achieved only in recent years.
-
1 month ago | 
dx.doi.org | Hao Wei |Yan Zhang |Nan-Nan Wang |Rong Fu
-
1 month ago | 
mdpi.com | Rong Fu |Min Zhang |Feng Wei |Miaomiao Lin
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
-
Jan 21, 2025 | 
bpspubs.onlinelibrary.wiley.com | Valerie Cosson |Rong Fu |Austin G. Kulasekararaj |Jun-Ichi Nishimura
What is already known about this subject Crovalimab is a novel C5 inhibitor for the treatment of paroxysmal nocturnal haemoglobinuria and in development for the treatment of other complement-mediated diseases. Crovalimab is a next-generation antibody that enables rapid and sustained C5 inhibition with subcutaneous, low-volume administration every 4 weeks in or outside of a healthcare setting, often with the option for self-administration.
-
Jan 20, 2025 | 
mdpi.com | Bao Wang |Rong Fu |Ling Qi |Liuzhu Zhu
1. IntroductionIn the face of the increasingly severe climate crisis and energy security challenges, actively promoting the construction of a new type of power system provides important support for realizing the goal of “peak CO2 emissions”. With the transformation of the energy structure, the uncertainty in the output of numerous widely distributed, small-scale renewable energy sources connected to the grid will exacerbate the operational security of the power system.
-
Dec 3, 2024 | 
chemistry-europe.onlinelibrary.wiley.com | Yi-Fan Ma |Dai-Yuan Li |Rong Fu |Zi-Hang Song
Supporting Information As a service to our authors and readers, this journal provides supporting information supplied by the authors. Such materials are peer reviewed and may be re-organized for online delivery, but are not copy-edited or typeset. Technical support issues arising from supporting information (other than missing files) should be addressed to the authors.
-
Nov 13, 2024 | 
onlinelibrary.wiley.com | Alexander Roth |Rong Fu |Guangsheng He |Hazzaa Alzahrani
1 Introduction Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, acquired, clonal haematological disease caused by a somatic mutation in the phosphatidylinositol glycan class A gene in haematopoietic stem cells [1-3]. In patients who do not receive adequate treatment, PNH is life-threatening; the 5-year mortality rate was approximately 35% between 1950 and 1995, prior to the development of modern targeted therapies [4].
-
Oct 27, 2024 | 
onlinelibrary.wiley.com | Shanshan Suo |Rong Fu |Albert Qin
Polycythaemia vera (PV), a common type of BCR/ABL-negative myeloproliferative neoplasm, is associated with an overproduction of red blood cells and a risk of developing thromboembolic (TE) events, post-PV myelofibrosis, and even acute leukaemia.1, 2 Phlebotomy-free, blood parameter control as measured by complete haematological response (CHR, i.e. haematocrit <45% without phlebotomy, a platelet count ≤400 × 109/L, and a white blood cell count <10 × 109/L) is an accepted efficacy end-point for...
-
Aug 27, 2024 | 
mdpi.com | Zhiyong Sheng |Yuanchun Huang |Yongxing Zhao |Rong Fu
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
